Sung-Yun Pai, MD, on Further Research With Lentiviral Gene Therapy for X-SCID

Video

The senior investigator at the National Cancer Institute Center for Cancer Research discussed unmet needs that remain and further research to be done.

“We are using low dose busulfan, which is still chemotherapy. These are very young infants; they are generally less than 6 months old at the time of treatment. And so, we are exposing them to chemotherapy that they don't necessarily need to have. So, the other advance, of course, would be to pair this very successful lentiviral vector with a nontoxic form of conditioning to eliminate enough of the stem cell compartment for the gene therapy transduced cells to engraft.”

Updated data from a phase 1/2 clinical trial (NCT03311503) demonstrated 100% survival and robust T-cell recovery more rapid than after standard hematopoietic stem cell transplantation (HCT) in patients with X-linked severe combined immunodeficiency (SCID-X1) that received lentiviral gene therapy delivering codon optimized IL2RG.

The data were presented by investigator Sung-Yun Pai, MD, chief, immune deficiency cellular therapy program, and tenured senior investigator, National Cancer Institute Center for Cancer Research, at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting, held May 16-20, in Los Angeles, California. CGTLive spoke with Pai to learn more about the next steps she would like to take in researching the lentiviral gene therapy. She also discussed the need for nontoxic conditioning, especially for diseases in which patients are very young, as in this study.

Click here to read more coverage of ASGCT 2023.

REFERENCE
Pai SY, Booth C, Kohn DB, et al. Universal survival and superior immune reconstitution after lentiviral gene therapy with low dose conditioning for X-linked SCID (SCID-X1). Presented at: ASGCT 2023 Annual Meeting; May 16-20; Los Angeles, California.
Recent Videos
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Related Content
© 2025 MJH Life Sciences

All rights reserved.